Table 1.

Demographics and CSF biomarker levels of the participant.

Group	Cases (N)	Age (Mean years ± SD)	Gender (female/male)	MMSE ± SD	CSF ABETA42 (pg/ml) ± SD	CSF P-TAU (pg/ml) ± SD	CSF TAU (pg/ml) ± SD	CX3CL1 (ng/ml) ± SD
Control	14	64 ± 2.92	7/8	29 ± 0.88	802 ± 218	59 ± 42	244 ± 46	0.31 ± 0.05
MCI	14	70 ± 3.52∗∗∗	9/5	26 ± 2.95∗∗	438 ± 58∗∗∗	112 ± 51∗	761 ± 374 n.s	0.28 ± 0.07
AD	14	68 ± 4.18∗	9/5	21.5 ± 3.5	453 ± 101∗∗∗	109 ± 46∗	762 ± 377 n.s	0.166 ± 0.05∗∗∗

Three groups of samples: C, control; MCI, mild cognitive impairment; AD, Alzheimer’s disease, with 14 cases (N) in each group, were analyzed. The average age, gender, memory test (MMSE), amount of CSF Aβ42, CSF ptau, CSF tau and CSF CX3CL1 are detailed in the table. Results are expressed as average concentration ± standard deviation (SD). Statistics of the measures are related to control: ^∗p ≤ 0.05, ^∗∗p ≤ 0.01, and ^∗∗∗p ≤ 0.001.